Melanotan II Side Effects

Reported Melanotan II side effects

The side-effect profile of MT-II is dose-dependent and largely driven by pan-melanocortin receptor activation. Many users experience the acute side effects as more limiting than the tanning benefit. Very Common (>50% of users): Nausea — the single most common complaint, particularly during the first 2-4 injections. Typically peaks 30-90 minutes post-injection and resolves within 2-4 hours. Dosing before bed (sleeping through the peak) and starting with very small doses (100-250 mcg) dramatically reduces nausea. Tolerance develops with repeated dosing. Facial flushing and warmth — MC1R activation dilates cutaneous vessels. Usually mild and transient. Spontaneous stretching and yawning — a classic melanocortin signature, occurring within 30-60 minutes of injection. Harmless but conspicuous. Spontaneous erections (men) — occur in a majority of male users during the hours after injection. Can be inconvenient or embarrassing in public settings and is one reason most users dose at night. Appetite suppression — 20-40% reduction in food intake is typical. Can be experienced as benefit or nuisance. Darkening of existing moles, freckles, and age spots — universal during active dosing. Some darkening persists after cessation; some normalizes over weeks. Common (10-50% of users): Injection site reactions — redness, swelling, mild bruising. Typically mild. Increased libido and sexual arousal — MC4R-mediated; some users welcome this, others find it disruptive. Transient hypertension — systolic blood pressure often rises 5-10 mmHg in the hours after injection. Usually clinically insignificant in healthy users but concerning in anyone with baseline hypertension. Headache — possibly vasomotor; often improves with hydration. Oily skin, acne flares — MC5R-mediated sebaceous gland activation. New freckles and ephelides — may appear on sun-exposed areas during MT-II courses, particularly on the face. Vivid dreams, sleep disturbance — reported by a subset of users. Uncommon but Notable: Emergence of new nevi (eruptive melanocytic nevi) — documented in multiple case reports during MT-II courses, sometimes numbering in the dozens. Often most dramatic on the trunk. Changes in existing mole morphology — darkening, asymmetry, border irregularity. Requires dermatologic evaluation to exclude melanoma transformation. This is the single most important dermatologic concern in MT-II use. Hyperpigmentation of lips, nipples, genitals — reflects high melanocortin receptor density in these tissues. Often not fully reversible. Priapism (prolonged painful erection) — rare but medically serious. More likely with concurrent PDE5 inhibitors or at high MT-II doses. Erection lasting more than 4 hours requires emergency evaluation. Mood changes — subset of users report increased irritability, anxiety, or low mood during MT-II courses. Rare but Serious: Rhabdomyolysis — a handful of case reports have documented muscle breakdown with MT-II use, possibly related to melanocortin effects on muscle metabolism. Presents with muscle pain and dark urine ([Ong et al., 2014]). Melanoma — several case reports and case series have documented melanoma diagnoses in MT-II users during or shortly after courses. Causation is not established, but the association is concerning enough that all reputable harm-reduction resources advise against MT-II in anyone with personal or family history of melanoma. Posterior reversible encephalopathy syndrome (PRES) — single case report of hypertension-associated PRES in an MT-II user ([Cousen et al., 2009]). Who should avoid MT-II entirely: Anyone with personal or family history of melanoma Anyone with many atypical nevi (dysplastic nevus syndrome, FAMMM syndrome) Fitzpatrick skin type I (very fair, always burns, never tans) — highest baseline melanoma risk Pregnant or breastfeeding women Anyone with uncontrolled hypertension or cardiovascular disease Anyone on PDE5 inhibitors (sildenafil, tadalafil) for ED due to priapism risk Anyone under age 18 Because of the product-quality and regulatory issues with grey-market MT-II, users also face risks that have nothing to do with pharmacology: bacterial contamination from poor aseptic reconstitution, endotoxin reactions from impure lyophilized powder, and wildly variable actual peptide content between vials from different vendors.

When to continue, reduce, or stop Melanotan II

Melanotan II contraindications

Absolute contraindications (do not use): Personal history of melanoma (any stage) Personal history of any skin cancer in atypical location or at young age Family history of melanoma, particularly first-degree relatives or FAMMM syndrome Dysplastic nevus syndrome or >50 atypical nevi Known BRAF, CDKN2A, or MC1R-loss-of-function mutations Fitzpatrick skin type I (always burns, never tans) — highest baseline melanoma risk Pregnancy or active attempt to conceive Breastfeeding Age < 18 Severe or uncontrolled hypertension (systolic > 160 or diastolic > 100) Recent cardiovascular event (MI, stroke, TIA within 6 months) Active significant arrhythmia Known hypersensitivity to melanocortin peptides Strong relative contraindications (use only with specialist oversight): Controlled hypertension on medication Coronary artery disease or significant cardiac risk factors History of priapism (from any cause) Psychiatric conditions that may be worsened by melanocortin effects (anxiety disorders, mood disorders during active episodes) Concurrent PDE5 inhibitor use History of rhabdomyolysis Immunocompromised state (grey-market product sterility risks are magnified) Renal or hepatic dysfunction severe enough to alter peptide clearance Drug interactions: PDE5 inhibitors (sildenafil, tadalafil, vardenafil): Combination produces highest-risk scenario for priapism. Avoid. Antihypertensive medications: MT-II's pressor effect may antagonize therapy; monitor blood pressure. Stimulants (amphetamines, pseudoephedrine, high-dose caffeine): Additive sympathetic activation and blood pressure effects. MAO inhibitors: Theoretical interaction given melanocortin effects on catecholamine signaling; avoid. Other melanocortin agonists (afamelanotide, grey-market α-MSH preparations, PT-141): Redundant pharmacology with additive side effects. Stop using immediately if: Any existing mole shows asymmetry, border irregularity, color variegation, or significant size change (ABCD warning signs) New pigmented lesion emerges that is irregular or concerning Erection persists longer than 4 hours (priapism — emergency evaluation) Chest pain, severe headache, blood pressure persistently > 160/100 Dark cola-colored urine or diffuse severe muscle pain (rhabdomyolysis concern) New-onset hives, facial swelling, difficulty breathing (allergic reaction) Significant mood change or suicidal ideation Any pregnancy test becomes positive Mandatory monitoring: Dermatologic full-body skin exam with mole mapping before first cycle and at least annually during any repeated use. Blood pressure check at baseline and within the first week of each cycle. Any new pigmented lesion during a cycle warrants dermatologic evaluation; do not assume it is "just MT-II activity." Note on medical supervision: Because MT-II is not approved and most US physicians will not prescribe or supervise its use, users are typically navigating these risks alone. At minimum, establish a relationship with a dermatologist who is willing to perform mole mapping without passing judgment — many dermatologists will do this for patients regardless of the reason for concern. The dermatologic surveillance is more important than any other aspect of harm reduction for MT-II users.

Why vendor quality drives Melanotan II side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Melanotan II side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .